

# Vikas A Gupta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6692708/publications.pdf>

Version: 2024-02-01

45  
papers

1,447  
citations

566801

15  
h-index

395343

33  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2130  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Nf2 Tumor Suppressor, Merlin, Functions in Rac-Dependent Signaling. <i>Developmental Cell</i> , 2001, 1, 63-72.	3.1	311
2	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1928-1937.	0.8	148
3	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019, 10, 1911.	5.8	109
4	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. <i>Blood Cancer Journal</i> , 2019, 9, 94.	2.8	104
5	Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. <i>Frontiers in Immunology</i> , 2019, 10, 1121.	2.2	103
6	Daratumumab in multiple myeloma. <i>Cancer</i> , 2019, 125, 2364-2382.	2.0	100
7	Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. <i>Blood</i> , 2017, 129, 1969-1979.	0.6	85
8	Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. <i>Cancer</i> , 2019, 125, 2991-3000.	2.0	73
9	Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. <i>Nature Communications</i> , 2020, 11, 1228.	5.8	62
10	The Juxtamembrane Wedge Negatively Regulates CD45 Function in B Cells. <i>Immunity</i> , 2005, 23, 635-647.	6.6	56
11	PI3K/Î³ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. <i>Blood</i> , 2022, 139, 523-537.	0.6	56
12	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , 2021, 137, 3604-3615.	0.6	44
13	Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma. <i>Leukemia</i> , 2019, 33, 1291-1296.	3.3	36
14	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. <i>Cancer</i> , 2019, 125, 416-423.	2.0	36
15	Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. <i>Cancer Biology and Therapy</i> , 2016, 17, 769-777.	1.5	17
16	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 3178-3189.	3.2	15
17	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021, 2, 600-615.	2.6	15
18	BCL2 Family Inhibitors in the Biology and Treatment of Multiple Myeloma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021, Volume 11, 11-24.	1.2	12

#	ARTICLE	IF	CITATIONS
19	B cells drive lymphocyte activation and expansion in mice with the CD45 wedge mutation and Fas deficiency. <i>Journal of Experimental Medicine</i> , 2008, 205, 2755-2761.	4.2	10
20	Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 519-531.	2.0	8
21	Downregulation of PA28 induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 125.	2.8	7
22	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , 2021, 96, E68-E71.	2.0	7
23	Preclinical Activity of Novel MCL1 Inhibitor AZD5991 in Multiple Myeloma. <i>Blood</i> , 2018, 132, 952-952.	0.6	6
24	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 75.e1-75.e7.	0.6	5
25	Approaches to Treating Multiple Myeloma, Now and Moving Forward. <i>JCO Oncology Practice</i> , 2020, 16, 15-16.	1.4	4
26	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 5647-5647.	0.6	3
27	Immunoglobulin Lambda Translocations Identify Poor Outcome and IMiD Resistance in Multiple Myeloma and Co-Occur with Hyperdiploidy. <i>Blood</i> , 2018, 132, 405-405.	0.6	3
28	$\beta_2$ adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma. <i>Haematologica</i> , 2022, 107, 2226-2231.	1.7	3
29	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2018, 132, 3294-3294.	0.6	2
30	Transcriptional and Post-Translational Regulation Of The Bcl-2 Family By IL-6 Mediates Resistance To ABT-737 In Multiple Myeloma. <i>Blood</i> , 2013, 122, 1924-1924.	0.6	2
31	CD45. , 2010, , 743-748.		1
32	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018, 132, 3241-3241.	0.6	1
33	Phosphorylation Influences The Binding Of Bim To Anti-Apoptotic Proteins In Multiple Myeloma. <i>Blood</i> , 2013, 122, 4446-4446.	0.6	1
34	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. <i>Blood</i> , 2018, 132, 5911-5911.	0.6	1
35	Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2013, , 41.	1.2	0
36	Transcriptional and Post-translational Regulation of the Bcl-2 Family by IL-6 Mediates Resistance to ABT-737 in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, S148.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Plasma Cell Neoplasms. , 2021, , 361-375.		0
38	P38 Is a Negative Regulator Of The Bortezomib-Induced Heat Shock Response In Multiple Myeloma. Blood, 2013, 122, 1929-1929.	0.6	0
39	Using RNA-Seq, SNP-CN and Targeted Deep Sequencing To Improve The Diagnostic Paradigm In Multiple Myeloma. Blood, 2013, 122, 1856-1856.	0.6	0
40	The Role of Proteasome Activator PA28Î± in Multiple Myeloma. Blood, 2019, 134, 5499-5499.	0.6	0
41	Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845. Blood, 2019, 134, 4413-4413.	0.6	0
42	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. Blood, 2021, 138, 1624-1624.	0.6	0
43	Mitochondrial Electron Transport Chain Inhibition Promotes Resistance to Proteasome Inhibitors in Multiple Myeloma. Blood, 2021, 138, 1611-1611.	0.6	0
44	Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era. Blood, 2020, 136, 20-21.	0.6	0
45	Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma. Blood, 2020, 136, 31-32.	0.6	0